{"id":"https://openalex.org/W7221615664","doi":"https://doi.org/10.3389/fphar.2026.1841871","title":"Economic evaluation of six immune checkpoint inhibitor-based first-line therapies for advanced squamous non-small-cell lung cancer: a cost-effectiveness analysis based on network meta-analysis","display_name":"Economic evaluation of six immune checkpoint inhibitor-based first-line therapies for advanced squamous non-small-cell lung cancer: a cost-effectiveness analysis based on network meta-analysis","publication_year":2026,"publication_date":"2026-10-13","ids":{"openalex":"https://openalex.org/W7221615664","doi":"https://doi.org/10.3389/fphar.2026.1841871","pmid":"https://pubmed.ncbi.nlm.nih.gov/42947700","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/13710048"},"language":"en","primary_location":{"id":"doi:10.3389/fphar.2026.1841871","doi":"https://doi.org/10.3389/fphar.2026.1841871","is_oa":true,"landing_page_url":"https://doi.org/10.3389/fphar.2026.1841871","pdf_url":"https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2026.1841871/pdf","source":{"id":"https://openalex.org/S132108250","display_name":"Frontiers in Pharmacology","issn_l":"1663-9812","issn":["1663-9812"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","ki-jl-1","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320527","host_organization_name":"Frontiers Media","host_organization_lineage":["https://openalex.org/P4310320527"],"host_organization_lineage_names":["Frontiers Media"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Pharmacology","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2026.1841871/pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5035798509","display_name":"Zijian Qiu","orcid":"https://orcid.org/0009-0007-6659-4824","observed_orcids":["https://orcid.org/0009-0007-6659-4824"]},"institutions":[{"id":"https://openalex.org/I27781120","display_name":"Wenzhou Medical University","ror":"https://ror.org/00rd5t069","country_code":"CN","type":"education","lineage":["https://openalex.org/I27781120"]},{"id":"https://openalex.org/I4210088331","display_name":"Quzhou City People's Hospital","ror":"https://ror.org/004qehs09","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I4210088331"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Zijian Qiu","raw_affiliation_strings":["Department of Radiation Oncology, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People\u2019s Hospital"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Radiation Oncology, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People\u2019s Hospital","institution_ids":["https://openalex.org/I27781120","https://openalex.org/I4210088331"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112110004","display_name":"Guodong Wang","orcid":"https://orcid.org/0000-0001-5191-7327","observed_orcids":["https://orcid.org/0000-0001-5191-7327"]},"institutions":[{"id":"https://openalex.org/I27781120","display_name":"Wenzhou Medical University","ror":"https://ror.org/00rd5t069","country_code":"CN","type":"education","lineage":["https://openalex.org/I27781120"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Guodong Wang","raw_affiliation_strings":["Department of Radiation Oncology, Zhuji Affiliated Hospital of Wenzhou Medical University"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Radiation Oncology, Zhuji Affiliated Hospital of Wenzhou Medical University","institution_ids":["https://openalex.org/I27781120"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5154252584","display_name":"Ying Lou","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I27781120","display_name":"Wenzhou Medical University","ror":"https://ror.org/00rd5t069","country_code":"CN","type":"education","lineage":["https://openalex.org/I27781120"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Ying Lou","raw_affiliation_strings":["Department of Medical Oncology, Zhuji Affiliated Hospital of Wenzhou Medical University"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology, Zhuji Affiliated Hospital of Wenzhou Medical University","institution_ids":["https://openalex.org/I27781120"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5101917638","display_name":"Xuan Feng","orcid":"https://orcid.org/0009-0001-5079-4385","observed_orcids":["https://orcid.org/0009-0001-5079-4385"]},"institutions":[{"id":"https://openalex.org/I27781120","display_name":"Wenzhou Medical University","ror":"https://ror.org/00rd5t069","country_code":"CN","type":"education","lineage":["https://openalex.org/I27781120"]}],"countries":["CN"],"is_corresponding":true,"raw_author_name":"Feng Xuan","raw_affiliation_strings":["Department of Radiation Oncology, Zhuji Affiliated Hospital of Wenzhou Medical University"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Radiation Oncology, Zhuji Affiliated Hospital of Wenzhou Medical University","institution_ids":["https://openalex.org/I27781120"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5101917638"],"corresponding_institution_ids":["https://openalex.org/I27781120"],"apc_list":{"value":3150,"currency":"CHF","value_usd":3801},"apc_paid":{"value":3150,"currency":"CHF","value_usd":3801},"fwci":0.0,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":{"value":0.79556133,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"17","issue":null,"first_page":"1841871","last_page":"1841871"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.9872999787330627,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},"topics":[{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.9872999787330627,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T12708","display_name":"Economic and Financial Impacts of Cancer","score":0.007000000216066837,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.00279999990016222,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/lung-squamous-cell-carcinoma","display_name":"lung squamous cell carcinoma","score":0.906000018119812},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitors","display_name":"immune checkpoint inhibitors","score":0.9929999709129333},{"id":"https://openalex.org/keywords/cost-effectiveness","display_name":"cost-effectiveness","score":0.8529999852180481},{"id":"https://openalex.org/keywords/pembrolizumab","display_name":"pembrolizumab","score":0.9350000023841858},{"id":"https://openalex.org/keywords/camrelizumab","display_name":"camrelizumab","score":0.9890000224113464},{"id":"https://openalex.org/keywords/penpulimab","display_name":"penpulimab","score":0.9710000157356262},{"id":"https://openalex.org/keywords/serplulimab","display_name":"serplulimab","score":0.8939999938011169},{"id":"https://openalex.org/keywords/tislelizumab","display_name":"tislelizumab","score":0.9929999709129333},{"id":"https://openalex.org/keywords/sugemalimab","display_name":"sugemalimab","score":0.9959999918937683},{"id":"https://openalex.org/keywords/combination-chemotherapy","display_name":"combination chemotherapy","score":0.5659999847412109},{"id":"https://openalex.org/keywords/quality-adjusted-life-years","display_name":"quality-adjusted life years","score":0.871999979019165},{"id":"https://openalex.org/keywords/incremental-cost-effectiveness-ratio","display_name":"incremental cost-effectiveness ratio","score":0.8130000233650208},{"id":"https://openalex.org/keywords/chinese-healthcare-system","display_name":"Chinese healthcare system","score":0.7170000076293945},{"id":"https://openalex.org/keywords/efficient-frontier","display_name":"efficient frontier","score":0.6370000243186951},{"id":"https://openalex.org/keywords/first-line-treatment","display_name":"first-line therapy","score":0.4230000078678131}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.845300018787384},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.786899983882904},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.6693000197410583},{"id":"https://openalex.org/C2780057760","wikidata":"https://www.wikidata.org/wiki/Q13896859","display_name":"Pembrolizumab","level":4,"score":0.6661999821662903},{"id":"https://openalex.org/C2776256026","wikidata":"https://www.wikidata.org/wiki/Q47912","display_name":"Lung cancer","level":2,"score":0.5496000051498413},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5109999775886536},{"id":"https://openalex.org/C2778336483","wikidata":"https://www.wikidata.org/wiki/Q5090632","display_name":"Chemotherapy regimen","level":3,"score":0.5038999915122986},{"id":"https://openalex.org/C2781413609","wikidata":"https://www.wikidata.org/wiki/Q7308373","display_name":"Regimen","level":2,"score":0.45809999108314514},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.3889000117778778},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.35589998960494995},{"id":"https://openalex.org/C10515644","wikidata":"https://www.wikidata.org/wiki/Q543310","display_name":"Survival analysis","level":2,"score":0.26440000534057617},{"id":"https://openalex.org/C2777714996","wikidata":"https://www.wikidata.org/wiki/Q7886","display_name":"Lung","level":2,"score":0.25949999690055847},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.2590000033378601},{"id":"https://openalex.org/C2777240266","wikidata":"https://www.wikidata.org/wiki/Q415220","display_name":"Pemetrexed","level":4,"score":0.25060001015663147}],"mesh":[],"locations_count":4,"locations":[{"id":"doi:10.3389/fphar.2026.1841871","doi":"https://doi.org/10.3389/fphar.2026.1841871","is_oa":true,"landing_page_url":"https://doi.org/10.3389/fphar.2026.1841871","pdf_url":"https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2026.1841871/pdf","source":{"id":"https://openalex.org/S132108250","display_name":"Frontiers in Pharmacology","issn_l":"1663-9812","issn":["1663-9812"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","ki-jl-1","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320527","host_organization_name":"Frontiers Media","host_organization_lineage":["https://openalex.org/P4310320527"],"host_organization_lineage_names":["Frontiers Media"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Pharmacology","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:13710048","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13710048/","pdf_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13710048/pdf/fphar-17-1841871.pdf","source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Front Pharmacol","raw_type":"Text"},{"id":"pmid:42947700","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/42947700","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in pharmacology","raw_type":"Journal Article"},{"id":"pmh:oai:doaj.org/article:c5633ff25d254252a29af91b750e85fe","doi":null,"is_oa":false,"landing_page_url":"https://doaj.org/article/c5633ff25d254252a29af91b750e85fe","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Frontiers in Pharmacology, Vol 17 (2026)","raw_type":"article"}],"best_oa_location":{"id":"doi:10.3389/fphar.2026.1841871","doi":"https://doi.org/10.3389/fphar.2026.1841871","is_oa":true,"landing_page_url":"https://doi.org/10.3389/fphar.2026.1841871","pdf_url":"https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2026.1841871/pdf","source":{"id":"https://openalex.org/S132108250","display_name":"Frontiers in Pharmacology","issn_l":"1663-9812","issn":["1663-9812"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","ki-jl-1","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320527","host_organization_name":"Frontiers Media","host_organization_lineage":["https://openalex.org/P4310320527"],"host_organization_lineage_names":["Frontiers Media"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Pharmacology","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9537000060081482}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W7221615664.pdf","grobid_xml":"https://content.openalex.org/works/W7221615664.grobid-xml"},"referenced_works_count":56,"referenced_works":["https://openalex.org/W1982967337","https://openalex.org/W2296800272","https://openalex.org/W2377410957","https://openalex.org/W2892640821","https://openalex.org/W3092126818","https://openalex.org/W3123873764","https://openalex.org/W3132994416","https://openalex.org/W3201987153","https://openalex.org/W3205783264","https://openalex.org/W3206290607","https://openalex.org/W4200067338","https://openalex.org/W4200204256","https://openalex.org/W4205569586","https://openalex.org/W4206071468","https://openalex.org/W4223452854","https://openalex.org/W4224951890","https://openalex.org/W4226093612","https://openalex.org/W4291464511","https://openalex.org/W4293102128","https://openalex.org/W4295079305","https://openalex.org/W4313543612","https://openalex.org/W4316810205","https://openalex.org/W4319068412","https://openalex.org/W4321787881","https://openalex.org/W4385264308","https://openalex.org/W4385863501","https://openalex.org/W4386416747","https://openalex.org/W4386688322","https://openalex.org/W4387692562","https://openalex.org/W4390589545","https://openalex.org/W4391275936","https://openalex.org/W4391407963","https://openalex.org/W4391933306","https://openalex.org/W4393935425","https://openalex.org/W4395008996","https://openalex.org/W4400501798","https://openalex.org/W4402297865","https://openalex.org/W4402828020","https://openalex.org/W4405994198","https://openalex.org/W4407888628","https://openalex.org/W4407935134","https://openalex.org/W4408149372","https://openalex.org/W4408636577","https://openalex.org/W4408820293","https://openalex.org/W4410775142","https://openalex.org/W4411265566","https://openalex.org/W4411435193","https://openalex.org/W4412354842","https://openalex.org/W4414152943","https://openalex.org/W4414553302","https://openalex.org/W4414671834","https://openalex.org/W4415388084","https://openalex.org/W4415623555","https://openalex.org/W7117458667","https://openalex.org/W7125432565","https://openalex.org/W7134824945"],"related_works":["https://openalex.org/W4415388084","https://openalex.org/W4399176716","https://openalex.org/W7166745287","https://openalex.org/W4200562740","https://openalex.org/W4385264308","https://openalex.org/W3081615089","https://openalex.org/W4400369488","https://openalex.org/W4291464511","https://openalex.org/W4376642570","https://openalex.org/W6902076766"],"abstract_inverted_index":{"Background:":[0],"Advanced":[1],"squamous":[2],"non-small-cell":[3],"lung":[4],"cancer":[5],"(sq-NSCLC)":[6],"imposes":[7],"a":[8,45],"substantial":[9],"clinical":[10],"and":[11,22,44,64,75,99,125,166,179,221,254,273],"economic":[12],"burden.":[13],"Immune":[14],"checkpoint":[15],"inhibitors":[16],"(sugemalimab,":[17],"tislelizumab,":[18],"penpulimab,":[19],"serplulimab,":[20],"camrelizumab,":[21],"pembrolizumab)":[23],"combined":[24],"with":[25,41],"chemotherapy":[26,85,110,129,147,151,157,169,178,182,193,213,227,245,267],"improve":[27],"survival,":[28],"but":[29,138],"their":[30],"comparative":[31],"cost-effectiveness":[32,77],"remains":[33],"uncertain.":[34],"Methods:":[35],"A":[36],"three-state":[37],"partitioned":[38],"survival":[39,271],"model":[40],"3-week":[42],"cycles":[43],"lifetime":[46],"horizon":[47],"was":[48,57,92,228],"developed":[49],"from":[50,59],"the":[51,107,131,153,173,184,195,205,209,229,239,248,264],"Chinese":[52],"healthcare-system":[53],"perspective.":[54],"Clinical":[55],"efficacy":[56],"derived":[58],"six":[60],"phase":[61],"3":[62],"trials":[63],"synthesized":[65],"using":[66],"network":[67],"meta-analysis.":[68],"Costs,":[69],"life-years":[70,73],"(LYs),":[71],"quality-adjusted":[72],"(QALYs),":[74],"incremental":[76,101,207],"ratios":[78],"(ICERs)":[79],"for":[80],"each":[81],"ICI-based":[82,118],"regimen":[83],"versus":[84,146,156],"were":[86,103,235,258],"estimated.":[87],"The":[88],"willingness-to-pay":[89],"(WTP)":[90],"threshold":[91],"set":[93],"at":[94,115,202],"$27,906/QALY.":[95,203],"Deterministic,":[96],"probabilistic,":[97],"scenario,":[98],"full":[100,206],"analyses":[102],"performed.":[104],"Results:":[105],"In":[106,204],"base-case":[108],"analysis,":[109,208],"alone":[111,158],"yielded":[112],"0.71":[113],"QALYs":[114,121],"$12,227.47.":[116],"All":[117],"regimens":[119],"increased":[120],"to":[122],"between":[123],"1.24":[124],"2.07.":[126],"Pembrolizumab":[127],"plus":[128,150,168,177,181,192,216,219,223,226,244],"provided":[130],"greatest":[132],"health":[133],"benefit,":[134],"yielding":[135],"2.07":[136],"QALYs,":[137],"had":[139,152,194],"an":[140],"ICER":[141,155],"of":[142,198],"$70,913.04":[143],"per":[144,160],"QALY":[145],"alone.":[148],"Penpulimab":[149],"lowest":[154],"($13,064.23":[159],"QALY),":[161],"followed":[162],"by":[163],"camrelizumab":[164,191,218,225,243],"($13,361.50/QALY),":[165],"tislelizumab":[167],"($14,022.95/QALY),":[170],"all":[171],"below":[172],"WTP":[174,241],"threshold.":[175,185],"Sugemalimab":[176],"serplulimab":[180],"exceeded":[183],"Probabilistic":[186],"sensitivity":[187],"analysis":[188],"indicated":[189],"that":[190],"highest":[196],"probability":[197],"being":[199],"cost-effective":[200],"(95%)":[201],"efficiency":[210],"frontier":[211],"comprised":[212],"alone,":[214],"penpulimab":[215],"chemotherapy,":[217,220],"pembrolizumab":[222],"chemotherapy;":[224],"preferred":[230,249],"strategy":[231,251],"after":[232,252],"dominated":[233,256],"options":[234],"excluded.":[236,259],"Conclusion:":[237],"At":[238],"selected":[240],"threshold,":[242],"may":[246],"be":[247],"first-line":[250],"strictly":[253],"extendedly":[255],"alternatives":[257],"This":[260],"finding":[261],"depends":[262],"on":[263],"indirect":[265],"comparisons,":[266],"baseline,":[268],"drug":[269],"prices,":[270],"extrapolation,":[272],"post-progression":[274],"assumptions.":[275]},"counts_by_year":[],"updated_date":"2026-11-01T11:40:01.658920","created_date":"2026-10-14T00:00:00"}